about
RNA-Based Vaccines in Cancer ImmunotherapyInduction of cytotoxic T lymphocytes primed with tumor RNA-loaded dendritic cells in esophageal squamous cell carcinoma: preliminary step for DC vaccine design.The notorious R.N.A. in the spotlight - drug or target for the treatment of diseaseManipulation of Innate and Adaptive Immunity through Cancer Vaccines.Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenesPluripotent state induction in mouse embryonic fibroblast using mRNAs of reprogramming factorsAntigen-specific cellular immunotherapy of leukemia.Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy.Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy.mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor ImmunityAntigen-presenting cells transfected with Hsp65 messenger RNA fail to treat experimental tuberculosis.Dendritic cell-based immunotherapy for myeloid leukemias.RNA as performance-enhancers for dendritic cells.Aerosolized Non-viral Nucleic Acid Delivery in the Vaginal Tract of Pigs.Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system.A Freeze-Concentration and Polyampholyte-Modified Liposome-Based Antigen-Delivery System for Effective Immunotherapy.A Targeted and Stable Polymeric Nanoformulation Enhances Systemic Delivery of mRNA to Tumors.Smart micelleplexes as a new therapeutic approach for RNA delivery.mRNA Cancer Vaccines.Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics.Immunization with truncated sequence of Telomerase Reverse Transcriptase induces a specific antitumor response in vivo.Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells.Generation and Cryopreservation of Clinical Grade Wilms' Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy.Chemically modified RNA activated matrices enhance bone regeneration.Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory propertiesLong-term in vivo imaging of translated RNAs for gene therapy.High-level antigen expression and sustained antigen presentation in dendritic cells nucleofected with wild-type viral mRNA but not DNA.RNA-based gene transfer for adult stem cells and T cells.Messenger RNA electroporation is highly efficient in mouse embryonic stem cells: successful FLPe- and Cre-mediated recombination.Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines.Immunotherapy for Pediatric Brain Tumors.Chronic Myelocytic Leukemia (CML) Patient-Derived Dendritic Cells Transfected with Autologous Total RNA Induces CML-Specific Cytotoxicity.Latest development on RNA-based drugs and vaccines.
P2860
Q26776028-3B7B9E82-4839-450E-A9C6-F3623A725262Q33595455-426ACA06-7DE8-4F38-9080-4DC57F658E6BQ33739733-67D98D67-75E1-4CAB-A943-4D12C350AD3CQ34552791-330DAC5E-D91E-440E-AC44-C606A5DE934AQ34721021-AAC9A4AC-CF82-4AF4-AEF5-4A2175B393F0Q34833754-61D4D82C-4C26-44F1-BC53-970C3D529075Q36240201-69FFE8C2-340C-40EF-B841-4F7961459E58Q36417403-6CA44BA1-DBA6-457E-AF63-32B8BD797DF3Q36673747-1DB09828-2D6C-4B7D-AF30-CB8ACE51A454Q36757007-2F73B747-EAE8-462D-A703-A64914693DDBQ37371021-99E6ECE3-8F3F-49A2-96F3-415A700E9D18Q37420778-39CED8B2-83EC-49EB-A2AF-DA354E82F68EQ37686532-CAF144DA-B6D6-4A40-8633-D2F89C408CA5Q37838639-EB52FA63-DFF9-4C7C-A88C-99BABC466F66Q38031222-A8669D24-5429-4E6F-83A8-07F907B0BE15Q38685236-52757AB5-701E-489F-8A2E-646ECC198B23Q38719141-EA3E410D-91A7-4C6A-8415-97936598D257Q38840111-D65B2512-F223-412B-8CDD-6515B0CB6F21Q39013357-F0B5887A-37C1-480F-A719-B9CBDFB9204AQ39829133-B151105B-CE49-436A-B668-82A9A3F05B4BQ40071763-E3B0B49B-D928-420D-9F24-9007CCB2849CQ40454655-552693DB-A41C-485D-B430-1E29F813E360Q40733554-4193F01C-2AAC-428E-9797-A32647FE2FCEQ41295229-A3F9B005-2E97-4625-B290-463C6439E5B4Q41945985-376D68E7-593F-4974-976E-321D5B68529DQ42242989-EF83DC49-0C96-4C2E-BD91-E1E99DC36BD2Q42751318-B9FC5BBE-3F93-4D9E-9720-6A4B3477D2FBQ45248732-BC9DEAEF-2D4C-41E9-91DD-68EFB59E7A39Q45877070-AC0E4769-A826-4474-BD37-A6576281BB37Q45881751-9A4F47A9-FC79-439B-ABFA-E9FC065062C4Q46407536-B9B28D1B-208D-4251-A004-E299C0DA9643Q47146006-693F6344-C745-41ED-8536-90BF80616958Q55231576-0C4B737F-6E42-4778-B8DF-0EDAF9029615
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Cancer immunotherapy using RNA-loaded dendritic cells.
@ast
Cancer immunotherapy using RNA-loaded dendritic cells.
@en
type
label
Cancer immunotherapy using RNA-loaded dendritic cells.
@ast
Cancer immunotherapy using RNA-loaded dendritic cells.
@en
prefLabel
Cancer immunotherapy using RNA-loaded dendritic cells.
@ast
Cancer immunotherapy using RNA-loaded dendritic cells.
@en
P2860
P1476
Cancer immunotherapy using RNA-loaded dendritic cells
@en
P2093
Z N Berneman
P2860
P304
P356
10.1046/J.1365-2249.2003.02286.X
P577
2003-12-01T00:00:00Z